Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 2: Immunotherapy in Lung Cancer-A Practical Case to Open Debate

Video Transcription

Video Summary

Dr. Jibum Lee from Yonsei Cancer Center discussed a case involving a 28-year-old female with metastatic adenocarcinoma and high PD-L1 expression. The patient's CT and PET scans revealed multiple metastases. Initial testing showed negative results for EGFR and ROS1, but liquid NGS identified KRAS and TP53 mutations. Despite the high PD-L1 score, Dr. Lee chose to treat her with pembrolizumab combined with chemotherapy (pemetrexed and carboplatin) due to her symptomatic and bulky disease. He highlighted the need for comprehensive molecular profiling and the consideration of combining immunotherapy with chemotherapy based on symptomatology and PD-L1 expression levels.

Asset Subtitle

Jii Bum (Joy) Lee, MD, PhD

Keywords

metastatic adenocarcinoma

PD-L1 expression

KRAS TP53 mutations

pembrolizumab chemotherapy

molecular profiling